Coagulopathy and Inflammation in Neonatal Heart Surgery: Mechanisms and Strategies

Annals of Thoracic Surgery

Volumn 81, Issue 6, 2006, Pages

  Jaggers, James ^a   Lawson, Jeffrey H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; PROTEINASE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CELL MIGRATION; CLINICAL FEATURE; DEGRANULATION; ENDOTHELIUM CELL; HEART SURGERY; HEMOSTASIS; HUMAN; INFLAMMATION; MORTALITY; NEUTROPHIL; NEWBORN SURGERY; PRIORITY JOURNAL; RESPIRATORY FAILURE; THROMBOCYTE ADHESION;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; APROTININ; APTAMERS, PEPTIDE; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; ENDOTHELIUM, VASCULAR; FACTOR VII; FACTOR XA; HEART DEFECTS, CONGENITAL; HEMOSTASIS; HUMANS; INFANT; INFANT, NEWBORN; INFLAMMATION MEDIATORS; POSTOPERATIVE COMPLICATIONS; RECEPTOR, PAR-1; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33646852234     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2006.02.072     Document Type: Article

References (67)

1. Grandaliano G., Valente A.J., and Abboud H.E. A novel biologic activity of thrombin. Stimulation of monocyte chemotactic protein production. J Exp Med 179 (1994) 1737-1741
2. Sower L.E., Froleich C.J., Carney D.H., Fenten J.W., and Klimpel G.R. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven transmembrane domain STD receptor for alpha-thrombin. J Immunol 155 (1995) 895-901
3. Seghaye M.C., Grabitz R.G., Faymonville M.L., Messmer B.J., Buro-Rathsmann K., and von Bernuth G. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. J Thorac Cardiovasc Surg 106 (1993) 978-998
4. Andrew M., Paes B., Milner R., et al. Development of the human coagulation system in the full term infant. Blood 70 (1987) 165-172
5. Andrew M., Paes B., and Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 92 (1990) 95-104
6. Harker L.A., Malpass D.J., and Branson H.E. Mechanisms of abnormal bleeding in patients undergoing cardiopulmonary bypass. acquired transient platelet dysfunction associated with selective alpha granule release. Blood 56 (1980) 824-834
7. Miller B.E., Bailey J.M., Mancuso T.J., et al. Functional maturity of the coagulation system in children. an evaluation using thromboelastography. Anesth Analg 84 (1997) 745-748
8. Esmon C.T. The impact of the inflammatory response on coagulation. Thromb Res 114 (2004) 321-327
9. ten Cate H., Schoenmakers S.H., Franco R., et al. Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med 29 Suppl (2001) S95-S97
10. Verrier E.D., and Boyle E.M. Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg 62 (1996) 915-922
11. Mann K.G. What is all the thrombin for?. J Thromb Hemost 1 (2003) 1504-1514
12. Ekert H., Gilchrist G.S., Stanton R., and Hammerand D. Hemostasis in cyanotic congenital heart disease. J Pediatr 76 (1970) 227-230
13. Kestin A.S., Valeri C.R., Khuri S.F., et al. The platelet function defect of cardiopulmonary bypass. Blood 82 (1993) 107-117
14. Greilich P.E., Brouse C.F., Beckman J., Jessen M.E., Martin E.J., and Carr M.E. Reductions in platelet contractile force correlate with duration of cardiopulmonary bypass and blood loss in patients undergoing cardiac surgery. Thromb Res 105 (2002) 523-529
15. Williams G.D., Bratton S.L., and Ramamoorthy C. Factors associated with blood loss and blood product transfusions. a multivariate analysis in children after open-heart surgery. Anesth Analg 89 (1999) 57-64
16. Esmon C.T. Role of coagulation inhibitors in inflammation. Thromb Haemost 86 (2001) 51-56
17. Knudsen L., Hasenkam M.J., Kure H.H., et al. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery. Thromb Res 84 (1996) 45-54
18. Brister S.J., Ofosu F.A., and Buchanan M.R. Thrombin generation during cardiac surgery. is heparin the ideal anticoagulant?. Thromb Haemost 70 (1993) 259-262
19. 1+2. Thromb Haemost 70 (1993) 253-258
20. Petaja J., Petola K., Sairenen H., et al. Fibrinolysis, antithrombin III and protein C in neonates during cardiac operations. J Thorac Cardiovasc Surg 112 (1996) 665-671
21. Boldt J., Knothe C., Schindler E., Welters A., Dapper F., and Hemplemann G. Thrombomodulin in pediatric cardiac surgery. Ann Thorac Surg 57 (1994) 1584-1589
22. Jaggers J., Neal M., Smith P.K., Ungerleider R.M., and Lawson J.H. Infant cardiopulmonary bypass. a procoagulant state. Ann Thorac Surg 68 (1999) 513-520
23. Bar-Shavit R., Kahn A., Mudd M.S., Wilner G.D., Mann K.G., and Fenton J.W. Localization of a chemotactic domain in human thrombin. Biochemistry 23 (1984) 397-400
24. Strukova S.M., Dugina T.N., Khgatian S.V., Redkozuba G.P., and Pinelis V.G. Thrombin mediated events implicated in mast cell activation. Semin Thromb Hemost 22 (1996) 145-150
25. Johnson K., Choi Y., DeGroot E., Samuels I., Creasey A., and Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 160 (1998) 5130-5135
26. Dèry O., Corvera C.U., Steinhoff M., and Bunnett N.W. Proteinase activated receptors. novel mechanisms of signaling by serine proteases. Am J Physiol 274 (1998) C1429-C1452
27. Sugama Y., Tiruppathi C., Offakievi K., Anderson T.T., Fenton J.W., and Malik A.B. Thrombin induced expression of endothelial P-selectin and intercellular adhesion molecule-1. A mechanism for stabilizing neutrophil adhesion. J Cell Biol 119 (1992) 935-944
28. Coleman R.W., and Schmaier A.H. Contact system. a vascular biology modulator with profibrinolytic, anticoagulant, antiadhesive and proinflammatory attributes. Blood 90 (1997) 3819-3843
29. Schmaier A.H. Plasma kallikrein system. a revised hypothesis for its activation and its physiologic contributions. Curr Opin Hematol 7 (2000) 261-265
30. Henderson L.M., Figueroa C.D., Muller-Esteral W., and Bhoola K.D. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood 84 (1994) 474-482
31. Lodge A.J., Chai P.J., Daggett C.W., Ungerleider R.M., and Jaggers J. Methylprednisolone reduces the inflammatory response to cardiopulmonary bypass in neonatal piglets, timing of dose is important. J Thorac Cardiovasc Surg 117 (1999) 515-522
32. Schwartz S.M., Duffy J.Y., Pearl J.M., Goins S., and Nelson D.P. Glucocorticoids preserve calpastatin and troponin I during cardiopulmonary bypass in immature piglets. Pediatr Res 54 (2003) 91-97
33. Schroeder V.A., Pearl J.M., Schwartz S.M., Shanley T.P., Manning P.B., and Nelson D.P. Combined steroid treatment for congential heart surgery improves oxygen delivery and reduces postbypass inflammatory mediator expression. Circulation 107 (2003) 2823-2828
34. Tassani P., Richter J.A., Barankay A., et al. Does high dose methylprednisolone in aprotinin treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures?. J Cardiothorac Vasc Anesth 13 (1999) 165-172
35. Alderman E.L., Levy J.H., Rich J., et al. International multi-center aprotinin graft patency experience. J Thorac Cardiovasc Surg 116 (1998) 716-730
36. Landis R.C., Asimakopoulos G., Poullis M., Haskard D.O., and Taylor K.M. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 72 (2001) 2169-2175
37. Khan T., Bianci C., Voisine P., Sandmeyer J., Jeng J., and Sellke F.W. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thoac Surg 79 (2005) 1545-1550
38. Poullis M., Manning R., Laffan M., Haskard D.O., Taylor K.M., and Landis R.C. The antithrombotic effect of aprotinin. actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg 120 (2000) 370-378
39. Asimakopoulos G., Thompson R., Nourshargh S., et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 120 (2000) 361-369
40. Boldt J., Knothe C., Zickmann B., Wege N., Dapper N., and Hempelmann G. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. influence on platelet function and blood loss. J Thorac Cardiovasc Surg 105 (1993) 705-711
41. Miller B.E., Tosone S.R., Tam V.K., et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 66 (1998) 535-541
42. D'Errico C.C., Munro H.M., and Bove E.L. Pro. the routine use of aprotinin during pediatric cardiac surgery is a benefit. J Cardiothorac Vasc Anesth 13 (1999) 782-784
43. Royston D. High-dose aprotinin therapy. a review of the first five years' experience. J Cardiothorac Vasc Anesth 6 (1992) 76-100
44. Oliver W.C., Fass D.N., Nuttall G.A., et al. Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 127 (2004) 1670-1677
45. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 29 (1985) 236-261
46. Royston D. High-dose aprotinin therapy. a review of the first five years' experience. J Cardiothorac Vasc Anesth 6 (1992) 76-100
47. Dietrich W., Mossinger H., Spannagl M., et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 105 (1993) 712-720
48. Poullis M., Manning R., and Laffan M. The antithrombotic effect of aprotinin. action mediated via the protease-activated receptor 1. J Thorac Cardiovasc Surg 120 (2000) 370-378
49. Day J.R., Punjabi P.P., Randi A.M., Haskard D.O., Landis R.C., and Taylor K.M. Clinical inhibition of the seven transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 110 (2004) 2597-2600
50. Reid R.A., Zimmerman A., Laussen P.C., Mayer J.E., Gorlin J.B., and Burrows F.A. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analg 84 (1997) 990-996
51. Chauhan S., Das S.N., Bisoi A., Kale S., and Kiran U. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vasc Anesth 18 (2004) 141-143
52. Hendriks H.G., van der Maaten J.M., de Wolf J., Waterbolk T.W., Sloof M.J., and van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 93 (2001) 287-289
53. Egan J.R., Lammi A., Schnell D.N., Gillis J., and Nunn G.R. Recombinant activated factor VII in pediatric cardiac surgery. Intensive Care Med 30 (2004) 682-685
54. Manno C.S., Hedberg K.W., Kim H.C., et al. Comparison of the hemostatic effects of fresh whole blood, and components after open heart surgery in children. Blood 77 (1991) 930-936
55. Mou S.S., Giroir B.P., Molitor-Kirsch E.A., et al. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med 351 (2004) 1635-1644
56. Campbell E.J., O'Byrne V., and Stratford P.W. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. ASAIO J 40 (1994) M853-M857
57. Murphy E.F., Keddie J.L., Lu J.R., Brewer J., and Russell J. The reduced adsorption of lysozyme at the phosphorylcholine incorporated polymer/aqueous solution interface studied by spectroscopic ellipsometry. Biomaterials 20 (1999) 1501-1511
58. DeSomer F., Francois K., and van Oeveren W. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg 18 (2000) 602-606
59. Baufreton C., Jansen P.G., and LeBesnerais P. Heparin coating with aprotinin reduces blood activation during coronary artery operations. Ann Thorac Surg 63 (1997) 50-56
60. Lappegard K.T., Fung M., Bergseth G., Reisenfeld J., and Mollness T.E. Artificial surface induced cytokine synthesis. effect of heparin coating and complement inhibition. Ann Thorac Surg 78 (2004) 38-45
61. Rubens F.D., Labow R.S., and Lavallee G.R. Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer. Ann Thorac Surg 67 (1999) 689-698
62. Taylor F.B., Chang A., and Ruf W. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33 (1991) 127-134
63. Taylor F., Chang A., and Peer G. Active site inhibited factor VIIa attenuates the coagulant and interleukin 6-8, but not tumor necrosis factor, responses of the baboon to LD100 E. coli. Blood 91 (1998) 1609-1615
64. Creasey A.A., Chang A.C., and Feigen L. Tissue factor pathway inhibitor reduces mortality from E. coli septic shock. J Clin Invest 91 (1993) 2850-2856
65. Rezaie A.R. DX-9065 inhibition of FXa and the prothrombinase complex. mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 89 (2003) 112-121
66. Nimjee S.M., Rusconi C.P., Harrington R.A., and Sullenger B.A. The potential of aptamers as anticoagulants. Trends Cardiovasc Med 15 (2005) 41-45
67. Dugina T.N., Kiseleva E.V., Chistov I.V., Umarova B.A., and Strukova S.M. Review. receptors of the PAR family as a link between blood coagulation and inflammation. Biochem Russia 67 (2002) 65-74